APOB and cholelithiasis: The missense variant rs150401285 (MAF = 0.1%) was associated with cholesterol (p = 4.9 × 10−14), LDL cholesterol (p = 1.1 × 10−13), and apolipoprotein B (p = 3.9 × 10−9) in GBE and with cholelithiasis and cholecystitis in PheWeb (p = 4.6 × 10−4), indicating that loss of ABCG5 activity due to rs150401285 results in a protective effect on gallstones.